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ABSTRACT 
Some diabetic foot ulcers, which are notoriously difficult to cure, are one of the most 
common health problems in diabetic patients .There are several surgical and medical 
options which already have been introduced for treatment of diabetic foot ulcers, so some 
patient will require amputation. The purpose of this study was to evaluate the efficacy of 
intravenous Semelil (ANGIPARSTM), a naive herbal extract to accelerate healing of 
diabetic foot ulcers. A multi-centric randomized controlled trial was conducted to evaluate 
intravenous Semelil for healing of diabetic foot ulcers. Sixteen diabetic patients were 
treated with intravenous Semelil, and nine other patients were treated with placebo as 
control group. Both groups were otherwise treated by wound debridement and irrigation 
with normal saline solution, systemic antibiotic therapy and daily wound dressing. Before 
and after intervention, the foot ulcer surface area was measured, by digital photography, 
mapping and planimetry. After 4 weeks, the mean foot ulcer surface area decreased from 
479.93±379.75 mm2 to 198.93±143.75 mm2 in the intervention group (p = 0.000) and from 
766.22±960.50 mm2 to 689.11±846.74 mm2 in the control group (p = 0.076). Average 
wound closure in the treatment group was significantly greater than placebo group (64% vs. 
25%, p= 0.015). This herbal extract by intravenous rout in combination with conventional 
therapy is more effective than conventional therapy by itself probably without side effect. 
However, further studies are required in the future to confirm these results in larger 
population. 
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INTRODUCTION 
It is estimated that 300 million persons worldwide 
will have diabetes by the year of 2025 (1). Today 
about 2566000 people (6%) are suffering from 
diabetes and its complications in Iran (2). 
Foot ulcers develop in approximately 15% of 
patients with diabetes, and foot disorders are a 
leading cause of hospitalization among such 
patients (3-5) and 15-20% of them require 
amputation. Neuropathy, poor circulation, and 
decreased resistance to infection are the three 
major contributors to the development of diabetic 
foot; which when present, foot deformities or 
minor trauma can readily lead to ulceration and 
infection(6). 
The overall rate of lower extremity amputation is 
4.1 per 1,000 person/years with diabetes as 
compared with about three per 10,000 
person/years in the entire population (7). High-
quality patient care and education has reduced the 
risk of amputation by 40–50% (8-9). The rate of 
lower limb amputation secondary to diabetic foot 
ulcer is higher in Iran than the global average 
(10).  
Several clinical studies have recently shown the 
efficacy of new therapies to heal foot ulcers in 
diabetics whose ulcers are associated with 
neuropathy (11-14). 
Novel therapeutic strategies and drugs are required 
for the treatment of diabetic foot ulcers (15). 
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Early studies suggest that Semelil 
(ANGIPARSTM) (a naive herbal extract) may have 
a role in healing of diabetic foot ulcers (16-18). 
Other studies have showen, Semelil without sever 
acute or chronic toxicity (17, 19-21). 
Considering the results of previous clinical trials 
(17, 18) we conducted a study to assess the 
therapeutic effects of intravenous Semelil in 
treatment of diabetic foot, to find a novel 
approach in treatment of diabetic foot ulcers. 
 
MATERIALS AND METHODS 
Experimental procedure was a randomized 
clinical trial, with a control group treated 
according to a conventional protocol, carried out 
on human with following details:  
  
Patients 
The study was designed as a Multi center 
Randomized Controlled Trial in Tehran 
(Endocrinology and Metabolism Research Center-
EMRC, Medical Sciences/ University of Tehran, 
Tehran, Iran), Tabriz (Endocrinology Research 
Center, Tabriz University of Medical Sciences, 
Tabriz, Iran), and Dubai (Internal Diseases Ward, 
Iranians’ Hospital, Dubai, UAE). A total number 
of 25 patients (M: 18; F: 7) were completed the 
study. Sixteen patients (M: 13; F: 3) received 
Semelil in addition to conventional therapy 
(treatment group) and nine patients (M: 5; F: 4) 
received only conventional therapy (control 
group). 
The method of randomization in each study 
 center was "Permuted Balanced Block" method. 
After initial assessments and obtaining inclusion 
criteria and signing the written informed consent, 
patients were allocated as treatment and control 
groups. 
All patients enrolled for the study suffered from 
chronic non-healing diabetic foot ulcer for several 
weeks to months according to the following 
inclusion criteria: 
• Patients with proven diabetes mellitus (type 1 
or 2) on medication either oral hypoglycemic 
or insulin. 
• Both genders, male or female patients between 
18 and 75 years of age. 
• Ulcers, which remained open without healing 
and had not shown improvement for more than 
2 weeks (irrespective of the ambulatory 
treatment administered). 
Patients with severe heart failure under treatment, 
with class III or higher functional classes of 
antiarrythmics and showing signs and symptoms 
of chronic and severe ischemia with pulse less 
lower limbs, and other disease or situation that 
impairs ulcer improvement (such as malignancies, 
vasculitis, etc.), alcohol and drug abuse, chronic 
renal failure and dialysis, progressive liver failure, 
corticosteroid consumption, immuno-suppressive 
therapy, radiotherapy, chemotherapy and any 
known drug hypersensitivity were excluded. 
For the Phase III study of ANGIPARSTM, patients 
were screened voluntarily after clear explanation 
of the nature of study for them. Informed written 
consent was obtained from each patient prior to 
recruitment. The study protocol was approved by 
the Medical Ethics Committee of Medical 
Sciences/ University of Tehran, Tehran, Iran.  
 
Methods 
Patients were treated and followed in 2 groups 
(intervention group): combination of 
ANGIPARSTM and conventional therapy, (control 
group): which received only conventional 
therapy) as follows:  
In intervention group, patients were treated by 
intravenous administration of ANGIPARSTM 4cc 
daily for 28 days. The drug diluted in 50-100 cc 
normal saline and infused during 30-60 minutes. 
Drug was kept away from light exposure and heat 
and was protected from the direct light during 
infusing. 
In both groups, other conventional and routine 
necessities such as betadine bath, antibiotic 
therapy, wound debridement, pressure 
decompression, and foot deformities corrections if 
required were employed.  
The Case Record Form had sections containing 
previous medical history of the patient, 
concomitant use of medications observations 
during active treatment with ANGIPARSTM, a 
section for recording adverse events and finally 
the investigator’s statement. 
Each patient was assessed for the following 
parameters: 
Exact inspection of ulcers, measurement of its 
diameters (including the longest length of the 
ulcer and the width perpendicular to it), by digital 
photography, mapping and planimetry to evaluate 
its improvement, steadiness or regression at the 
beginning, at the end of the second week and at 
the end of the forth week of the investigation 
(during digital photography laying a ruler beside 
the ulcer is necessary and ulcers must be saved 
with patient's name and date). 
Daily inspection of the ulcer before drug 
admission and change of the dressing, debride the 
wound between treatment periods according to 
physicians' diagnosis, physical examination and 
history at the beginning of the research, and 
recording any probable side effect and necessary 
managements at the end of the second week and at 
the end of the forth week  
Necessary laboratory assessments (e.g. Na, K, 
CBC, PT, PTT, ALT, AST, Bilirubin, ALK 
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Phosphatase and Amylase) and EKG at the 
beginning, at the end of the second week and at 
the end of the forth week of investigation were 
assessed. Biochemical variables were estimated 
by standard laboratory methods. 
 
Statistical methods 
Data were collected from different sources and 
analyzed statistically using SPSS 11 (SPSS Inc, 
Chicago, Illinois). Tests for Normality were 
performed for all quantitative outcome variables. 
Levene's and heterogeneity tests were used for 
equality of variances and efficacy of results 
among study centers, respectively. Independent 
and paired t-tests were used for comparison 
between pretreatment and posttreatment test 
results between groups and within groups, 
respectively. Chi square test was performed for 
qualitative variables. Two-tailed significance level 
of P-value<0.05 was accepted. All data are 
presented as mean±SD. 
 
RESULT 
A total of 25 subjects (M: 18; F: 7) were enrolled 
into the study. The baseline characteristics data 
are presented in Table 1. The baseline 
characteristics of subjects had no statistically 
significant difference in comparison with sixteen 
patients received ANGIPARSTM in addition to 
conventional therapy and nine patients whom only 
received conventional therapy alone. 
There were no statistically significant differences 
between two groups about laboratory assessments 
over the 4-weeks of study. 
Before treatment, the mean foot ulcer area in the 
treatment and control groups were 479.93±379.75 
mm2 and 766.22±960.50 mm2 respectively 
(P=0.413). After 4 week treatment the mean ulcer 
surface area was compared between the two 
groups (ANGIPARSTM and conventional and 
conventional alone therapy by itself) to determine 
the effects of both treatment protocols (Table 2).  
The percentage of decrease in ulcer surface area 
differs significantly in the treatment group (64%) 
compared with the control group (25%) 
(P=0.015). 
The effect of intravenous administration of 
ANGIPARS™ on healing of some patients’ foot 
ulcers are illustrated in Figure 1. 
All patients tolerated treatment by intravenous 
ANGIPARS™ very well. There were no adverse 
effects to report. 
 
DISCUSSION 
From the results, the potential efficacy of 
intravenous ANGIPARS™ as an adjunct to 
conventional wound care have been convincingly 
shown in patients with diabetic foot ulcers, that 
probably would decrease the amputation rate. 
Early researches have suggested that 
ANGIPARS™ therapy may have a role in 
acceleration of wound healing (17, 18). Attempts 
have made to use ANGIPARS™ in encouraging 
wound healing in diabetics. 
Our finding showed that foot ulcer surface area 
decreased after 28 days with the drug and 
conventional therapy compared with conventional 
therapy alone. 
Four recent studies have suggested that healing 
progression at 2nd to 4th weeks are good predictors 
of eventual wound closure (22-25). In our study 
healing percent of wound was 64% for 
ANGIPARS™.  
The majority of recent investigations have shown 
that one of the most common problems in diabetic 
patients is delayed wound repair due to vascular 
insufficiency and decreased blood flow (24-26). 
Establishing appropriate blood flow over the 
affiliated limb is the robust goal of the treatment 
that eminently improves healing process (29, 30). 
Some investigations for patophysiological effect 
of ANGIPARS™ have revealed that this drug 
probably improves total tissue blood flow and 
oxygenation (Unpublished data).  
Decreased blood flow may result in insufficient 
oxygen delivery, which makes healing impossible 
unless angioplasty or a vascular bypass is 
performed. Another contributing factor is micro 
vascular disease. It is generally considered that 
improved blood supply, through angiogenesis, for 
example, may improve ulcer healing. 
Our results indicate that the herbal extract by 
intravenous rout in combination with conventional 
therapy is more effective than conventional 
therapy alone and is without any side effect (17-
21). This drug can be used probably in all types of 
diabetic foot ulcers. 
This new treatment decreased mean duration of 
hospitalization and direct and indirect costs and 
probably decreased amputation rate in patients 
with diabetic foot ulcer. 
From results it may be concluded that 
ANGIPARS™ is useful in healing process of 
diabetic foot ulcers, it would be wise to use this 
preparation in patients. 
 
Larijani et al / DARU 2008 16 (Suppl. 1) 35-40 
 
38
The absence of any significant side effect 
indicates that ANGIPARS™ could well become a 
part of routine therapy for diabetic foot ulcers. 
However, further studies with greater sample size 
are necessary for evaluation of the effects on other 
variables, such as hemoglobin A1C. In con-
clusion, our results support the contention that 
ANGIPARS™, in addition to good foot care, is 
more effective than conventional alone in healing 
diabetic ulcers, and may assist in reducing healing 
times.  
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Table 1. Baseline characteristics of subjects among treatment and control groups 
Variable Treatment group (n=16) 
Control group 
(n=9) P value 
Male (%) Sex 
Female (%) 
13 (81.2)a 
3 (18.8) a 
5 (55.6%) a 
4 (44%) a NS 
Age (years) 50.6(12.65 ) b 59(10.95) b NS 
Weight (kg) 73.07(18.2) b 65.42(9.44) b NS 
Duration of DM (years) 10.64(4.76) b 14.83(9.64) b NS 
I Type of DM II 
2 (12.5) a 
14 (87.5) a 
0 
9 (100) a NS 
Size of wound (mm2) 479.93(379.75) b 766.22(960.5) b NS 
FBS (mg/dl) 182.85(74.42) b 155(35.35) b NS 
  a Number (%),  b Mean(SD)            
  FBS, fasting blood sugar; NS, not significant 
 
 Table 2. wound size before and after treatment among two groups 
P value After  (mm²) Before  (mm ²) Group 
0.000 198.93±143.75 479.93±379.75 Treatment (ANGIPARS™) 
0.076 689.11±846.74 766.22±960.50 Control 
 
 
 
Before                                             4 weeks   After 
Figure 1. Photographs of patients before & after treatment with ANGIPARS™. 
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